drugset / Trial / NCT02209792
Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this extension study was to obtain long-term safety data for BIRB 796 BS in patients with moderate to severe Crohn's disease after 26 weeks of treatment. Secondary objectives were the evaluation of efficacy of BIRB 796 BS to induce clinical remission and response over 26 weeks of treatment.
Timeline
- Start
- 2001-10
- Primary completion
- 2004-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIBR 796 BS | Unknown | 10 mg | Oral |
| Subject | BIBR 796 BS | Unknown | 20 mg | Oral |
| Subject | BIBR 796 BS | Unknown | 30 mg | Oral |
| Subject | BIBR 796 BS | Unknown | 60 mg | Oral |